Ceralasertib
Ceralasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase ATR.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | 3 | 1 | — | — | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 4 | — | — | — | 5 |
| Triple negative breast neoplasms | D064726 | — | 3 | — | — | — | 3 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 3 | — | — | — | 3 |
| Neoplasms | D009369 | C80 | 2 | 1 | — | — | — | 3 | |
| Adenocarcinoma | D000230 | — | 2 | — | — | — | 2 | ||
| Bile duct neoplasms | D001650 | — | 2 | — | — | — | 2 | ||
| Melanoma | D008545 | — | 2 | — | — | — | 2 | ||
| Endometrial neoplasms | D016889 | EFO_0004230 | 1 | 1 | — | — | — | 2 | |
| Squamous cell neoplasms | D018307 | — | 1 | — | — | — | 1 | ||
| Osteosarcoma | D012516 | — | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma of head and neck | D000077195 | 1 | — | — | — | — | 1 | ||
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | — | — | — | — | 1 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 1 | — | — | — | — | 1 | |
| Colorectal neoplasms | D015179 | 1 | — | — | — | — | 1 | ||
| Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | 1 | — | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Colonic neoplasms | D003110 | C18 | 1 | — | — | — | — | 1 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | — | — | — | — | 1 | |
| Leukemia | D007938 | C95 | 1 | — | — | — | — | 1 | |
| Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CERALASERTIB |
| INN | ceralasertib |
| Description | Ceralasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase ATR. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1COCCN1c1cc(C2([S@](C)(=N)=O)CC2)nc(-c2cc[nH]c3nccc2-3)n1 |
Identifiers
| PDB | — |
| CAS-ID | 1352226-88-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4285417 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 85RE35306Z (ChemIDplus, GSRS) |
Target
Agency Approved
ATR
ATR
Organism
Homo sapiens
Gene name
ATR
Gene synonyms
FRP1
NCBI Gene ID
Protein name
serine/threonine-protein kinase ATR
Protein synonyms
Ataxia telangiectasia and Rad3-related protein, FRAP-related protein 1, FRAP-related protein-1, MEC1, mitosis entry checkpoint 1, homolog
Uniprot ID
Mouse ortholog
Atr (245000)
serine/threonine-protein kinase ATR (Q9JKK8)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 303 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more